Rigel has an exclusive license agreement with Dr. Reddy’s to develop and commercialize REZLIDHIA (olutasidenib) in all potential indications throughout Dr. Reddy’s territory*.
Rigel received an upfront cash payment with the potential for additional regulatory and commercial milestone payments and tiered royalty payments for products sold in Dr. Reddy’s territory.
*Includes Latin America, South Africa, certain countries in the Commonwealth of Independent States (CIS), India, certain countries in Southeast Asia and North Africa, Australia and New Zealand